Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GenFleet to Receive Royalty Rights for Conducting China Trial of BioLineRx Cancer Drug

publication date: Jun 29, 2022

Shanghai’s GenFleet Therapeutics will conduct a Phase IIb China clinical trial of BioLineRx’s Motixafortide as a first-line therapy for patients with pancreatic ductal adenocarcinoma (PDAC). GenFleet will be responsible for all costs of the 200-patient trial. In return, the company will be eligible for low-to-mid single digit royalties on global sales of the drug. GenFleet is a novel drug development company, not a clinical trial partner, so GenFleet may be interested in combining Motixafortide with its own candidates. In the trial, Motixafortide will be tested together with a PD-1 and chemotherapy. BioLineRx is a Tel Aviv biopharma. More details....

Stock Symbols: (NSDQ: BLRX; TASE: BLRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital